: Avinger stock rockets off a record low after launch of vascular disease treatment system


Shares of Avinger Inc. skyrocketed 63.5% on heavy volume in morning trading Monday, enough to make them the biggest gainers trading on major U.S. exchanges, after the medical device company announced the commercial launch of its Tigereye ST, an image-guided catheter-based system for the diagnosis and treatment of vascular disease. Trading volume soared to 26.5 million shares, compared with the full-day average of about 9,300 shares. “This device represents one of the most significant advancements in Avinger’s image-guided technologies for the treatment of peripheral artery disease,” said Chief Medical Officer Jaafer Golzar. “The unique combination of onboard image-guidance, steerability, ease of use, and crossing power expands the number of patients eligible for minimally invasive revascularization,” Golzar added. The stock, which closed Friday at a record low of $4.14, has now shed 58.5% year to date, while the S&P 500 SPX, +0.28% has gained 16.1%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleThe Ratings Game: Disney stock sentiment has been weak, but here’s why one new bull sees upside
Next articleThe latest U.S. News college rankings are out. Why do we all care so much?


Please enter your comment!
Please enter your name here